Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies
Sponsor: Sunesis Pharmaceuticals
Listed as NCT00446342, this PHASE1 trial focuses on B-lymphoid Malignancies and Chronic Lymphocytic Leukemia and remains completed. Sponsored by Sunesis Pharmaceuticals, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — May 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunesis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .